Digital Therapeutics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Digital Therapeutics Market Trends and Insights

Rising Chronic Disease Burden Demands Scalable Intervention Platforms

The digital therapeutics market is growing rapidly due to the increasing prevalence of chronic diseases, which demand scalable care models beyond traditional in-person support. Diabetes remains a key focus area because of its significant care burden, measurable outcomes, and the ability for payers to link digital interventions with medication adherence, glycated hemoglobin levels, and hospitalization risks. Cleveland Clinic's findings on the Twin Precision Treatment platform demonstrated its potential in reducing medication use for type 2 diabetes, strengthening the case for software-driven cardiometabolic care. This approach is now extending to obesity, hypertension, and cardiovascular risk management, where digital programs are integrated with drug therapies and coaching to enhance adherence and care continuity. 

AI-Enabled Personalization Raises the Clinical Performance Bar

Personalization is becoming a critical factor in the digital therapeutics market as static content fails to engage diverse patient profiles or improve outcomes effectively. A 2025 trial highlighted the success of Lumen, an AI-driven voice coach, in delivering problem-solving therapy with results comparable to human coaching.^{[1]Personalized Game-Based Digital Intervention for Relieving Depression and Anxiety Symptoms, A Pilot RCT,” npj Mental Health Research, nature.com} Another study emphasized the benefits of reinforcement learning in personalizing interventions for depression and anxiety, showing significant improvements over non-personalized approaches. Buyers are increasingly prioritizing AI-driven solutions that enhance clinical responses and reduce care costs. Vendors offering patient-specific adaptations are better positioned in coverage discussions, particularly in mental health and chronic disease programs, where dropout rates remain a challenge. This trend is raising the performance standards across the market.

Regulatory Normalization of SaMD Creates Institutional Access Pathways

Regulatory developments are providing a stronger commercial foundation for the digital therapeutics market. The FDA's Digital Health Center of Excellence, in collaboration with CMS and CMMI, launched the TEMPO Pilot in January 2026, linking digital device access with patient outcome measurement. In the U.S., the Access to Prescription Digital Therapeutics Act of 2025 aims to establish a dedicated Medicare Part B benefit for prescription digital therapeutics, reducing reliance on inconsistent pricing. Germany's DiGA pathway reported 695,000 activated prescriptions in 2025, with cumulative reimbursement costs reaching EUR 400 million (USD 432 million). From 2026, Germany will require at least 20% of DiGA reimbursement pricing to be tied to measurable outcomes, raising evidence standards and emphasizing real-world reporting.^{[2]GKV-Spitzenverband, “DiGA Report 2025,” cited in DUX Healthcare, dux-healthcare.com} Similar frameworks in Japan, Australia, and South Korea are further stabilizing institutional pathways for digital therapeutics.

Accelerating Payer Adoption Through Outcome-Linked Contracting

Payers are increasingly adopting digital therapeutics as evidence of cost savings drives selective contracting. A study showed that SleepioRx, a digital CBT platform for insomnia, reduced first-year total healthcare costs by USD 2,083 per patient, with pharmacy spending decreasing by 46%. Another 2026 study highlighted cost reductions and improved efficiency in employer-sponsored behavioral health programs through digitally enabled access.^{[3] A. Nwosu et al., “Policy and Reimbursement Strategies to Improve Patient Access to Prescription Digital Therapeutics,” npj Digital Medicine, nature.com} Fee-for-service models are growing rapidly as institutional buyers prefer contracts tied to measurable usage and outcomes. While coverage remains selective, payers are more willing to support programs for high-cost chronic conditions when aligned with existing administrative systems. This shift is moving the market closer to value-based care structures.

Reimbursement Fragmentation Constrains Scalable Commercial Models

The digital therapeutics market faces limited commercial access due to fragmented reimbursement frameworks across payers, countries, and care settings. In the U.S., the 2025 Physician Fee Schedule introduced G-codes for digital mental health devices, but the absence of national pricing leaves access reliant on contractor-level pricing and local billing processes. Reimbursement strategies for prescription digital therapeutics vary widely, with policy design playing a critical role in patient access, provider adoption, and commercial scalability. This creates a divide between companies capable of managing extended coverage timelines and those restricted to employer-direct or cash-pay models. 

Engagement Attrition Undermines Real-World Evidence Generation

Patient drop-offs remain a significant issue in the digital therapeutics market, as lower completion rates weaken clinical impact and the evidence base required for broader coverage. The average completion rate for digital depression interventions is 44.2%, ranging from 1.8% to 94%, highlighting the importance of design quality, patient fit, and onboarding experience. Real-world persistence in musculoskeletal digital therapeutics also remains low despite proven efficacy, necessitating coordinated efforts from patients, clinicians, developers, and health systems to sustain usage. 

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Type: Software Anchors Revenue, But Services Redraw the Growth Map

In 2025, software solutions held 53.78% of the digital therapeutics market, driven by app-based therapy models that bypass the need for specialized hardware. This segment thrived due to rapid distribution, seamless updates, and reduced delivery costs, establishing it as the commercial backbone for early and mid-stage players. Hardware remained the smallest segment, primarily serving a supportive role integrated with sensors, wearables, or other connected devices. Software's centrality in the digital therapeutics market was reinforced, especially in scenarios where mobile interfaces sufficed for clinical pathways without requiring remote monitoring.

Services are projected to grow at a 27.10% CAGR from 2026 to 2031, reflecting a shift in buyer preferences toward managed care layers around software. Health systems, payers, and employers increasingly value care navigation, coaching, reporting, and implementation support to enhance activation, continuity, and accountability. This shift is driving the market toward ongoing program delivery rather than one-time licensing or app subscriptions. Software remains the core therapeutic engine, while services emerge as the commercial layer translating adoption into measurable outcomes.

By Application: Prevention Dominates, Management Captures the Growth Premium

Prevention accounted for 42.25% of the digital therapeutics market in 2025, supported by strong adoption in diabetes prevention, smoking cessation, and weight management. These areas had established a solid commercial foundation due to employer and health plan funding for preventive measures with familiar behavior-change models. Prevention's lower clinical complexity compared to prescription treatments enabled broader deployment across large member pools, making it the largest application segment in 2025. However, growth is now shifting toward active disease management.

Management is expected to grow at a 28.56% CAGR through 2031, driven by rising demand for programs demonstrating cost-offset benefits in cardiometabolic care and chronic conditions. Omada Health reported Q1 2026 revenue of USD 78 million, a 42% year-over-year increase, with total members exceeding 1.02 million, showcasing the scalability of management-focused platforms. Treatment remains the smallest segment due to stricter authorization and evidence requirements, but the revenue mix is increasingly favoring management as payers prioritize cost-control programs over general wellness initiatives.

By Indication: Diabetes Holds Share, CNS Disorders Command Growth

Diabetes held 29.55% of the indication-level digital therapeutics market in 2025, solidifying its position as the primary entry point for software-driven therapeutic care. Diabetes programs benefit from measurable outcomes like glycated hemoglobin levels and hospitalization risks, facilitating payer contracts and employer purchases. The adoption of GLP-1 therapies further strengthens this position, with digital coaching and adherence support complementing cardiometabolic treatment pathways. Diabetes remains the foundational indication, offering scalability and an evidence framework extendable to adjacent conditions.

CNS disorders are forecast to grow at a 28.76% CAGR through 2031, driven by advancements in ADHD, depression, schizophrenia, and related mental health areas. Lumos Labs' 510(k) clearance for LumosityRx in December 2025 as a prescription digital therapeutic for adult ADHD highlights the competitive momentum in this space. Click Therapeutics and Boehringer Ingelheim's USD 50 million Series D investment in April 2026 aims to commercialize CT-155 for schizophrenia’s experiential negative symptoms, showcasing the strengthening of pharma partnerships in CNS-focused digital therapeutics. 

By Business Model: DTC Dominates but Fee-for-Service Signals Structural Shift

In 2025, the direct-to-consumer model captured 60.34% of the digital therapeutics market, reflecting the widespread adoption of app-based distribution and employer-sponsored wellness initiatives. This model enabled quick user access and allowed vendors to scale without relying on comprehensive clinical reimbursement. It aligned with the market's early dynamics, where products gained traction through direct engagement, cash payments, or employer benefits. While DTC led in 2025, the market is now shifting toward more accountable payment frameworks.

Fee-for-service is projected to grow at a 29.15% CAGR through 2031, signaling a shift toward contracts tied to utilization and outcomes. Institutional buyers are prioritizing accountability in activation, adherence, and clinical usage, making fee-for-service contracts more appealing than traditional subscription models. The business-to-business segment remains significant, particularly where vendors collaborate with employers, health systems, or health plans to offer white-labeled or tailored care solutions. 

By End User: Patients Lead Volume, Providers Drive Fastest Adoption

In 2025, patients accounted for 34.55% of the end-user mix, highlighting the pivotal role of consumer-centric delivery in the digital therapeutics market. Direct access, mobile distribution, and minimal entry barriers positioned patients at the forefront of adoption, particularly for programs not requiring formal prescriptions or intensive provider oversight. Meanwhile, provider-led utilization is gaining importance, driven by clearer billing codes, clinical pathways, and integration into standard care. Patients remained the largest end-user segment in 2025, while providers are expected to play a more prominent role during the forecast period.

Providers are projected to grow at a 27.44% CAGR from 2026 to 2031, supported by clearer reimbursement pathways and a shift toward clinician-prescribed digital solutions. A 2025 study highlighted that while physicians still view digital therapeutics as complementary tools, their integration into multimodal care and guideline-linked practices is increasing with clearer reimbursement avenues. Payers and employers are also becoming significant end users, focusing on measurable outcomes, contract structures, and medical cost impacts. 

Geography Analysis

In 2025, North America accounted for 41.25% of the global digital therapeutics market, making it the largest regional contributor by revenue and the most commercially advanced market. This leadership stemmed from the FDA's regulatory framework, a strong employer self-insurance base, active venture-backed developments, and institutional readiness for software-driven care models. The 2025 Physician Fee Schedule introduced reimbursement codes for digital mental health treatment devices, creating a formal billing mechanism despite pending national pricing. 

Europe remained the second-largest regional market, with Germany leading due to its DiGA model, the most structured national reimbursement pathway for digital therapeutics. In 2025, the DiGA program recorded 695,000 activated prescriptions, costing EUR 171 million (USD 184 million), reflecting 64% year-over-year growth. From January 2026, Germany required at least 20% of DiGA reimbursement pricing to be tied to measured outcomes, favoring platforms with robust real-world data systems. Other European countries, including the UK, France, Italy, and Spain, are progressing gradually, while partnerships like GAIA and Daiichi Sankyo Europe demonstrate the use of the German pathway for broader commercialization.

The Asia-Pacific region is the fastest-growing digital therapeutics market, with a projected CAGR of 27.60% from 2026 to 2031. Growth is driven by rising chronic disease prevalence, expanding digital health infrastructure, and formal software-as-medical-device pathways in Japan, South Korea, and Australia. By 2025, South Korea approved 14 digital therapeutics products, including the insomnia treatment Somzz, showcasing regulatory progress. Japan's PMDA framework and Australia's TGA pathway are advancing structured approval and reimbursement processes, particularly in mental health and diabetes care.